TERN-501

Experimental drug for nonalcoholic steatohepatitis

{{Drugbox | verifiedfields = changed | verifiedrevid = 123456789 | IUPAC_name = (2S)-2-[[4-[2-[[(1R,2R)-2-(4-chlorophenyl)cyclopropyl]amino]-2-oxoethyl]phenyl]amino]-3-phenylpropanoic acid | image = TERN-501.svg | image2 = | width = 200 | alt = | caption = Chemical structure of TERN-501 | tradename = | synonyms = | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 12345678 | DrugBank = | ChemSpiderID = 12345678 | UNII = | KEGG = | ChEMBL = 1234567 | SMILES = | StdInChI = | StdInChIKey = }}

TERN-501 is an investigational drug being developed for the treatment of nonalcoholic steatohepatitis (NASH), a progressive form of nonalcoholic fatty liver disease (NAFLD). TERN-501 is a selective thyroid hormone receptor beta (THR-β) agonist, designed to target liver tissue specifically, thereby reducing the risk of side effects associated with systemic thyroid hormone activation.

Mechanism of Action

TERN-501 functions by selectively activating the thyroid hormone receptor beta (THR-β) in the liver. This receptor plays a crucial role in regulating lipid metabolism, which is often disrupted in patients with NASH. By activating THR-β, TERN-501 aims to reduce liver fat content, inflammation, and fibrosis, which are key pathological features of NASH.

Development and Clinical Trials

TERN-501 is currently undergoing clinical trials to evaluate its safety and efficacy in patients with NASH. Early-phase trials have focused on determining the optimal dosing regimen and assessing the pharmacokinetics and pharmacodynamics of the drug. Subsequent trials aim to evaluate the impact of TERN-501 on liver histology and clinical outcomes in patients with NASH.

Potential Benefits

The selective action of TERN-501 on THR-β is intended to minimize the side effects commonly associated with thyroid hormone therapies, such as cardiovascular and bone-related adverse effects. This selectivity is expected to provide a safer therapeutic option for patients with NASH, a condition for which there are currently limited treatment options.

Challenges and Considerations

While TERN-501 shows promise, the development of therapies for NASH is challenging due to the complex pathophysiology of the disease and the need for long-term treatment. The efficacy of TERN-501 will need to be demonstrated in large-scale clinical trials, and its long-term safety profile will need to be thoroughly evaluated.

Related Pages

• Nonalcoholic steatohepatitis
• Thyroid hormone receptor
• Nonalcoholic fatty liver disease
• Lipid metabolism